Clinical Trial Update: Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of AST-120 in GERD patients who remain symptomatic on standard-dose proton pump inhibitors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AST-120 (AST-120)

Snippet

Sponsor: Ocera Therapeutics | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 2 | Status: TERMINATED